BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38847983)

  • 1. Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions.
    Scholfield DW; Fitzgerald CWR; Boe LA; Eagan A; Levyn H; Xu B; Tuttle RM; Fagin JA; Shaha AR; Shah JP; Wong RJ; Patel SG; Ghossein R; Ganly I
    Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38847983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer.
    Alswailem M; Alghamdi B; Alotaibi A; Aljomiah A; Al-Hindi H; Murugan AK; Abouelhoda M; Shi Y; Alzahrani AS
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e704-e711. PubMed ID: 36995892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
    Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
    Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
    Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
    [No Abstract]   [Full Text] [Related]  

  • 6. RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis.
    Bulanova Pekova B; Sykorova V; Mastnikova K; Vaclavikova E; Moravcova J; Vlcek P; Lancova L; Lastuvka P; Katra R; Bavor P; Kodetova D; Chovanec M; Drozenova J; Matej R; Astl J; Hlozek J; Hrabal P; Vcelak J; Bendlova B
    Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37882481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High
    Wang Z; Tang P; Hua S; Gao J; Zhang B; Wan H; Wu Q; Zhang J; Chen G
    Onco Targets Ther; 2022; 15():147-157. PubMed ID: 35173448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype.
    Ullmann TM; Thiesmeyer JW; Lee YJ; Beg S; Mosquera JM; Elemento O; Fahey TJ; Scognamiglio T; Houvras Y
    Ann Surg Oncol; 2022 Mar; ():. PubMed ID: 35230579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Detailed Histologic and Molecular Assessment of the Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma.
    Chou A; Qiu MR; Crayton H; Wang B; Ahadi MS; Turchini J; Clarkson A; Sioson L; Sheen A; Singh N; Clifton-Bligh RJ; Robinson BG; Gild ML; Tsang V; Leong D; Sidhu SB; Sywak M; Delbridge L; Aniss A; Wright D; Graf N; Kumar A; Rathi V; Benitez-Aguirre P; Glover AR; Gill AJ
    Mod Pathol; 2023 Dec; 36(12):100329. PubMed ID: 37716505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
    Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
    Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
    Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Diffuse Sclerosing Variant Papillary Thyroid Carcinoma in Pediatric Patients.
    Brady C; Manning SC; Rudzinski E; Paulson V; Wang X; Liu YJ; Parikh SR; Bonilla-Velez J; Hawkins DS; Dahl J
    Laryngoscope; 2022 May; 132(5):1132-1138. PubMed ID: 34713899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
    Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
    Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing.
    Jin L; Zhou L; Wang JB; Tao L; Lu XX; Yan N; Chen QM; Cao LP; Xie L
    Int J Endocrinol; 2024; 2024():2470721. PubMed ID: 38268989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
    Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
    Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
    Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.